Takeda Pharmaceutical Co Ltd (NYSE:TAK)
$ 13.44 -0.01 (-0.07%) Market Cap: 42.64 Bil Enterprise Value: 69.87 Bil PE Ratio: 22.79 PB Ratio: 0.95 GF Score: 79/100

Full Year 2019 Takeda Pharmaceutical Co Ltd Earnings Call Transcript

May 14, 2019 / 12:00PM GMT
Release Date Price: $17.92 (-8.06%)
Takashi Okubo
Takeda Pharmaceutical Company Limited - Global Head of IR, Global Finance

Thank you, everyone. Thank you for attending Takeda's conference call for the results announcement for fiscal 2018. We just announced the full year results 6 hours ago followed by the web presentation. Then we -- this is the global conference call in English.

I would like to introduce the management team of the management: Mr. Christophe Weber, CEO; and Mr. Andy Plump, President of Research and Development; and Mr. Costa Saroukos, CFO; also Julie Kim, President of Plasma-Derived Therapy Business Unit. So you will be well covered tonight.

So we would like to start with a brief opening remark by Christophe. Please.

Christophe Weber
Takeda Pharmaceutical Company Limited - President, CEO & Representative Director

Thank you very much for joining. I don't think we have a long presentation right now because we just -- you probably have seen the presentation. So what I suggest is that Costa do -- does a few statements, just summarizing the overall picture,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot